Network pharmacology to decipher the mechanism of Danggui Longhui Wan against chronic myeloid leukemia

Abstract

Chronic myeloid leukemia (CML) is a hematopoietic myeloproliferative disorder. The Chinese prescription Danggui Longhui Wan (DGLHW) has been utilized in CML treatment, but its underlying mechanisms remain unclear. In this study, we gathered 794 constituents, 1249 drug targets, 1654 disease genes and 129 intersection genes. GO and KEGG were used to analyze the function of these genes. Compatibility of prescription study showed that monarch drug, minister drug, assistant and guide drug played a synergistic role in the treatment of CML. In addition, we obtained 20 hub genes and 12 key components. Molecular docking indicated that the main compounds and core proteins had good binding ability. The results of this study also showed that DGLHW might play a role in the treatment of CML by affecting MAPK, PI3K/AKT, FoxO and p53 signaling pathways.

Keywords

chronic myeloid leukemia / Danggui Longhui Wan / network pharmacology / compatibility analysis

Conflict of interest

The authors declare no conflict of interest.

References

[1] Flis S, Chojnacki T. Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities. Drug Des Devel Ther, 2019, 13: 825-843.

[2] Osman AEG, Deininger MW. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. Blood Rev, 2021, 49: 100825.

[3] Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol, 2003, 40: 4-10.

[4] Barreto Vianna DR, Gotardi J, Baggio Gnoatto SC, et al. Natural and Semisynthetic Pentacyclic Triterpenes for Chronic Myeloid Leukemia Therapy: Reality, Challenges and Perspectives. Chem Med Chem, 2021, 16: 1835-1860.

[5] Younes S, Ismail MA, Al-Jurf R, et al. Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies. Hematology, 2023, 28: 2196866.

[6] Alves R, Gonçalves AC, Rutella S, et al. Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance. Cancers (Basel), 2021, 13: 4820.

[7] Perabo FG, Frössler C, Landwehrs G, et al. Indirubin-3’- monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer. Anticancer Res, 2006, 26: 2129-2135.

[8] Yu XG, Qiao J, Wang C, et al. Determination of 3 components in Danggui Longhui Pills by RP-HPLC. Northwest Pharm J, 2021, 36: 386-389.

[9] Gaboriaud-Kolar N, Myrianthopoulos V, Vougogiannopoulou K, et al. Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines. J Nat Prod, 2016, 79: 2464-2471.

[10] Guo MF, Dai YJ, Gao JR, et al. Uncovering the Mechanism of Astragalus membranaceus in the Treatment of Diabetic Nephropathy Based on Network Pharmacology. J Diabetes Res, 2020, 2020: 5947304.

[11] Ni M, Liu X, Meng Z, et al. A bioinformatics investigation into the pharmacological mechanisms of javanica oil emulsion injection in non-small cell lung cancer based on network pharmacology methodologies. BMC Complement Med Ther, 2020, 20: 174.

[12] Gfeller D, Grosdidier A, Wirth M, et al. Swiss Target Prediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res, 2014, 42: W32-W38.

[13] Clough E, Barrett T. The Gene Expression Omnibus Database. Methods Mol Biol, 2016, 1418: 93-110.

[14] Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res, 2013, 41: D991-D995.

[15] Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res, 2015, 43: D447-452.

[16] Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 2003, 13: 2498-2504.

[17] Ji X, Tang J, Zhang J. Effects of Salt Stress on the Morphology, Growth and Physiological Parameters of Juglansmicrocarpa L. Seedlings. Plants (Basel), 2022, 11: 2381.

[18] Märkl F, Huynh D, Endres S, et al. Utilizing chemokines in cancer immunotherapy. Trends Cancer, 2022, 8: 670-682.

[19] Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature, 2010, 463: 676-680.

[20] Minciacchi VR, Kumar R, Krause DS. Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future. Cells, 2021, 10: 117.

[21] Bugler J, Kinstrie R, Scott MT, et al. Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML. Front Cell Dev Biol, 2019, 7: 136.

[22] Mondal S, Adhikari N, Banerjee S, et al. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview. Eur J Med Chem, 2020, 194: 112260.

[23] He ZK, Xue S, Zhang YH, et al. Expression Levels of JARID1B, Hes1 and MMP-9 Genes in CML Patients Treated with Imatinib Mesylate. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2019, 27: 1071-1076.

[24] Rao Q, Xie K, Varier KM, et al. Design, Synthesis, and Antileukemic Evaluation of a Novel Mikanolide Derivative Through the Ras/Raf/MEK/ERK Pathway. Front Pharmacol, 2022, 13: 809551.

[25] Blažević T, Heiss EH, Atanasov AG, et al. Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases. Evid Based Complement Alternat Med, 2015, 2015: 654098.

[26] Xiao Z, Hao Y, Liu B, et al. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma, 2002, 43: 1763-1768.

[27] Saraei R, Rahman HS, Soleimani M, et al. Kaempferol sensitizes tumor necrosis factor-related apoptosis- inducing ligand-resistance chronic myelogenous leukemia cells to apoptosis. Mol Biol Rep, 2022, 49: 19-29.

[28] Huang G, Yin Z, Wang X, et al. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells. Phytomedicine, 2023, 117: 154918.

[29] Rakshit S, Mandal L, Pal BC, et al. Involvement of ROS in chlorogenic acid-induced apoptosis of Bcr-Abl+ CML cells. Biochem Pharmacol, 2010, 80: 1662-1675.

[30] Hassanzadeh A, Hosseinzadeh E, Rezapour S, et al. Quercetin Promotes Cell Cycle Arrest and Apoptosis and Attenuates the Proliferation of Human Chronic Myeloid Leukemia Cell Line-K562 Through Interaction with HSPs (70 and 90), MAT2A and FOXM1. Anticancer Agents Med Chem, 2019, 19: 1523-1534.